AU2018287018B2 - Cannabidiolic acid esters compositions and uses thereof - Google Patents

Cannabidiolic acid esters compositions and uses thereof Download PDF

Info

Publication number
AU2018287018B2
AU2018287018B2 AU2018287018A AU2018287018A AU2018287018B2 AU 2018287018 B2 AU2018287018 B2 AU 2018287018B2 AU 2018287018 A AU2018287018 A AU 2018287018A AU 2018287018 A AU2018287018 A AU 2018287018A AU 2018287018 B2 AU2018287018 B2 AU 2018287018B2
Authority
AU
Australia
Prior art keywords
disease
cbda
nausea
rats
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018287018A
Other languages
English (en)
Other versions
AU2018287018A1 (en
Inventor
Christeen Haj
Raphael Mechoulam
Linda Parker
Roger Pertwee
Reem Smoum
Joseph Tam
Aron WELLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical University of Guelph
Publication of AU2018287018A1 publication Critical patent/AU2018287018A1/en
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, UNIVERSITY OF GUELPH reassignment YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD Request for Assignment Assignors: BAR ILAN UNIVERSITY, UNIVERSITY OF GUELPH, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
Application granted granted Critical
Publication of AU2018287018B2 publication Critical patent/AU2018287018B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2018287018A 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof Active AU2018287018B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
US62/522,243 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2018287018A1 AU2018287018A1 (en) 2020-01-30
AU2018287018B2 true AU2018287018B2 (en) 2022-04-28

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018287018A Active AU2018287018B2 (en) 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof

Country Status (12)

Country Link
US (1) US11440870B2 (enExample)
EP (1) EP3509638B1 (enExample)
JP (1) JP2020524679A (enExample)
CN (1) CN111032088A (enExample)
AU (1) AU2018287018B2 (enExample)
BR (1) BR112019026916A2 (enExample)
CA (1) CA3067512A1 (enExample)
DK (1) DK3509638T3 (enExample)
ES (1) ES2909350T3 (enExample)
MX (1) MX389847B (enExample)
PT (1) PT3509638T (enExample)
WO (1) WO2018235079A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3067512A1 (en) 2017-06-20 2018-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
AU2019412836A1 (en) * 2018-12-25 2021-07-01 Epm (Ip), Inc. Cannabidiolic acid esters for cosmetic or edible compositions
US12403114B2 (en) * 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
EP4017485A1 (en) 2019-08-22 2022-06-29 EPM Group, Inc. Cannabinoid acid ester compositions and uses thereof
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
US20240000808A1 (en) * 2020-11-16 2024-01-04 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022137144A1 (en) * 2020-12-24 2022-06-30 Buzzelet Development And Technologies Ltd. Compositions comprising cannabinoid acid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298579A1 (en) * 2009-04-29 2010-11-25 Thc Pharm Gmbh Process for preparing synthetic cannabinoids
WO2015158381A1 (en) * 2014-04-16 2015-10-22 Vivacell Biotechnology España S.L. Novel cannabidiol quinone derivatives
US20150336874A1 (en) * 2013-09-03 2015-11-26 Symrise Ag Mixtures of cannabinoid compounds, and production and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) * 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
ES2224658T3 (es) 1998-05-04 2005-03-01 The University Of Connecticut Nuevos canabinoides selectivos hacia el receptor cb2.
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
AU2006297300B2 (en) * 2005-09-29 2012-05-10 Albany Molecular Research, Inc. Process for production of delta-9-tetrahydrocannabinol
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
CA3067512A1 (en) 2017-06-20 2018-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298579A1 (en) * 2009-04-29 2010-11-25 Thc Pharm Gmbh Process for preparing synthetic cannabinoids
US20150336874A1 (en) * 2013-09-03 2015-11-26 Symrise Ag Mixtures of cannabinoid compounds, and production and use thereof
WO2015158381A1 (en) * 2014-04-16 2015-10-22 Vivacell Biotechnology España S.L. Novel cannabidiol quinone derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETRZILKA T ET AL, "123. SYNTHESE VON HASCHISCH-INHALTSSTOFFEN", HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA, CH, (1969-01-01), vol. 52, no. 123, PART 04, doi:10.1002/HLCA.19690520427, ISSN 0018-019X, pages 1102 - 1133 *
YUKIHIRO SHOYAMA ET AL, "Cannabis. X. The isolation and structures of four new propyl cannabinoid acids, tetrahydrocannabivarinic acid ... cannabigerovarinic acid, from Thai Cannabis, 'Meao variant'.", CHEM & PHARM BULL, 25(9), p.2306-2311 *

Also Published As

Publication number Publication date
ES2909350T3 (es) 2022-05-06
MX389847B (es) 2025-03-20
BR112019026916A2 (pt) 2020-06-30
EP3509638B1 (en) 2022-01-12
JP2020524679A (ja) 2020-08-20
EP3509638A1 (en) 2019-07-17
PT3509638T (pt) 2022-03-02
CN111032088A (zh) 2020-04-17
DK3509638T3 (da) 2022-04-11
MX2019015311A (es) 2022-02-02
US11440870B2 (en) 2022-09-13
WO2018235079A1 (en) 2018-12-27
US20200115317A1 (en) 2020-04-16
AU2018287018A1 (en) 2020-01-30
CA3067512A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
AU2018287018B2 (en) Cannabidiolic acid esters compositions and uses thereof
Pertwee et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats
CN105517989B (zh) 大麻素类化合物的混合物及其制备和用途
AU2012248061B2 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
ES2972711T3 (es) Tratamiento de enfermedades del CNS con estimuladores de la GCs
CN102274227B (zh) 粉防己碱在制备预防和/或治疗抑郁症药物中的应用
JP2003529527A (ja) 抗炎症薬および鎮痛薬として有用な（３ｒ，４ｒ）−δ８−テトラヒドロカンナビノール−１１−酸
TW201309666A (zh) 一種取代桂皮醯胺衍生物、製備方法及其應用
US8492431B2 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US9822117B2 (en) Pyridoindolobenz[b,d]azepine derivatives and uses thereof
ES2605466T3 (es) Compuesto de benzacepina
Class et al. Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL)
CN101379063A (zh) 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
EP2964331B1 (en) Pentacyclic pyridoindolo[b,e]azepine derivatives and uses thereof
MX2012002551A (es) Compuestos para tratar desordenes o enfermedades asociados con la actividad del receptor de neuroquinina 2.
CN108218814A (zh) 靶向sirt3激动剂及其在aml治疗药物中的应用
CN101016329A (zh) 以介芬胺为原料制备环杷明的方法
CN107446010A (zh) 一种红霉素衍生物及其制备方法和应用
CN102228696B (zh) 聚乙二醇-聚乙烯醇共聚物-美他沙酮前药及其合成方法
CN102503953B (zh) 肟类化合物
CN110003157A (zh) 一种具有抗焦虑作用的新型黄酮类化合物及其应用
ES2694110T3 (es) Fármaco profiláctico o terapéutico para el estreñimiento
US20170174708A1 (en) PENTACYCLIC PYRIDOINDOLOBENZO[b,e]DIAZEPINES AND THIAZEPINES FOR TREATING CNS DISORDERS

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF GUELPH

Free format text: FORMER APPLICANT(S): UNIVERSITY OF GUELPH; YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD; BAR ILAN UNIVERSITY

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD

Free format text: FORMER APPLICANT(S): UNIVERSITY OF GUELPH; YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD; BAR ILAN UNIVERSITY

FGA Letters patent sealed or granted (standard patent)